Johnson & Johnson · JNJ · FY2026 Q1 · Calendar Q2 2026

J&J edges past Q1 estimates and raises 2026 guidance

J&J's beat and guidance raise rest on launch momentum in Innovative Medicine (ICOTYDE, INLEXZO) and MedTech (VARIPULSE Pro, TECNIS PureSee), plus execution toward the planned mid-2027 Orthopedics separation. Management's double-digit-growth-by-decade-end ambition and $55B U.S. manufacturing commitment underpin a confident tone. The stock did not hold an outsized reaction on the day (a modestly negative abnormal move) and has drifted lower since, so the thesis is one of execution risk against an ambitious outlook rather than a clean fundamental win.

Why did JNJ rise 0.9% after beating EPS estimates in FY2026 Q1?

Research this report with FN2. Free to start; review your question before sending.

Reported Before market openNYSEHealthcare $652.31B market cap
100quality score

Earnings scorecard

Reported versus consensus
Reported EPS $2.70 Consensus $2.68
EPS surprise +0.7% Reported versus consensus
Reported revenue $24.06B Consensus $23.61B
Revenue surprise +1.9% Reported versus consensus
Check the math in the surprise calculator >

Market reaction

prior-close to event-session close
Stock move +0.9% Event window
SPY move +1.2% Same window
Abnormal move -0.3% Stock minus SPY
Volume 1.4× Versus trailing sessions
Subsequent drift -6.6% Up to 20 sessions
JNJSPY benchmark

Ask FN2 about JNJ FY2026 Q1

Choose a question to continue your research

Free to start. Your question opens in chat for you to review and send. FN2 can look up the transcript, financials and prior quarters.

Transcript intelligence

What changed

J&J reported Q1 FY2026 with adjusted EPS of $2.70 versus the $2.68 estimate and revenue of $24.06B versus the $23.61B estimate. Management raised full-year 2026 sales guidance to a midpoint of $100.2-$100.8B, lifted adjusted EPS guidance by $0.02, and increased the dividend 3.1% to $5.36 per share.

Guidance delta

raised

Key takeaways

  • Adjusted Q1 EPS of $2.70 beat the $2.68 estimate and revenue of $24.06B beat the $23.61B estimate.
  • Q1 operational sales grew 6.4%, with Innovative Medicine up 7.4% and MedTech up 4.6%.
  • Full-year 2026 sales guidance raised to a $100.2-$100.8B midpoint and adjusted EPS guided $0.02 higher.
  • Dividend increased 3.1% to $5.36 per share, marking 64 consecutive years of growth.
  • $55B committed to U.S. manufacturing and R&D through 2029, with $12B already invested.

Management priorities

  • Execute launches of ICOTYDE, INLEXZO, VARIPULSE Pro and TECNIS PureSee as growth engines.
  • Hold the raised 2026 sales and EPS guidance while protecting adjusted operating margin.
  • Advance the planned separation of the Orthopedics business by mid-2027.
  • Deploy the $55B U.S. manufacturing and R&D investment program through 2029.

Follow JNJ with an agent that reads every filing, transcript, and price print. Free to start.

Try FN2 free

Earnings History

Estimate Beat Miss Match
JNJ REVENUE earnings history estimate and actual scatter chart 10 reported fiscal quarters and 2 future estimate-only quarters. Q2 '24 estimate $22B Q2 '24 actual $22B, beat Q3 '24 estimate $22B Q3 '24 actual $22B, beat Q2 '25 estimate $23B Q2 '25 actual $24B, beat Q3 '25 estimate $24B Q3 '25 actual $24B, beat Q4 '25 estimate $24B Q4 '25 actual $25B, beat Q1 '26 estimate $24B Q1 '26 actual $24B, beat Q2 '26 estimate $25B Q2 '26 actual $25B, beat Q3 '26 estimate $25B Q3 '26 actual $25B, match Q4 '26 estimate $26B Q1 '27 estimate $26B
Show 2 more >

Analyst Consensus ?

ConsensusHold40 ratings
Bullish2152.5%
Neutral1640.0%
Bearish37.5%

Analyst 52W Price Targets

$270.47Current
$90Low
$230.82Average
$320High

Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Nov 22, 2026. Not an FN2 forecast.

Firm-level rating actions

FMP grade actions identify the grading firm, not a named analyst.

FirmRatingPrior ratingActionDate
Wells Fargo Overweight OverweightMaintainOct 16, 2026
Morgan Stanley Overweight OverweightMaintainOct 15, 2026
RBC Capital Outperform OutperformMaintainOct 14, 2026
Leerink Partners Outperform OutperformMaintainOct 14, 2026
Guggenheim Buy BuyMaintainOct 7, 2026
Show 35 more rating actions

Named analyst price targets

Upside is calculated against the persisted current price $270.47. FMP does not supply a rating on these named-analyst rows.

FirmAnalyst52W targetPrice when postedUpsideDate
Evercore ISIAnalyst unavailable$300$258.74 +10.9%Oct 20, 2026
Wells FargoLarry Biegelsen$287$253.28 +6.1%Oct 16, 2026
BernsteinLee Hambright$270$259.85 -0.2%Oct 15, 2026
RBC CapitalAnalyst unavailable$280$251.68 +3.5%Oct 14, 2026
Leerink PartnersAnalyst unavailable$272$251.75 +0.6%Oct 14, 2026
See 103 more

Track every rating change on JNJ the moment it posts. Free to start.

Start free

Company context

Snapshot as of publication

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Historical context

All JNJ earnings

Healthcare peers this season

Latest reports in the same sector
CompanyQuarterEPS surpriseMarket moveHeadline
ASND Ascendis Pharma A/S FY2026 Q3 · Calendar Q4 2026 +38.7% +3.0% Ascendis Q3 growth broadens the story, while execution risks remain
ALC Alcon Inc. FY2026 Q3 · Calendar Q4 2026 +2.2% -2.3% Alcon holds FY outlook as new launches meet IOL competition

Latest beats and misses

Who reports next

Get the JNJ recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Sources

  1. Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
  2. FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
  3. Polygon adjusted daily market bars · 2026-09-25T21:41:07.855996+00:00
  4. Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-09-25T21:41:07.853171+00:00

Methodology

Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.

Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.

Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.

By FN2 Research · Updated · As of 2026-09-25. For educational purposes only; not investment advice.